Every material Form 8-K Aeluma, Inc. has filed with the SEC since July 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aeluma disclosed that CEO Jonathan Klamkin terminated a Rule 10b5-1 trading arrangement on October 21, 2026. The plan, adopted May 23, 2026, provided for the sale of up to 300,000 shares of common stock. The filing does not state whether any shares were sold under the plan.
Plan adopted May 23, 2026 by Jonathan Klamkin, President, CEO and Chairman, allowing sale of up to 300,000 shares
Klamkin terminated the 10b5-1 trading arrangement on October 21, 2026
Plan was previously reported in the Annual Report on Form 10-K for the fiscal year ended June 30, 2026
Aeluma, Inc. reported fiscal 2026 results for the year ended June 30, 2026, with full-year revenue of $4.5 million, down from $4.7 million, and a net loss of $9.2 million, up from $3.0 million. The company said the losses reflected investments in new hires and manufacturing readiness, and it had $56.0 million in cash and cash equivalents at year-end, which it says will support its commercialization plans.
Q4 fiscal 2026 revenue was $0.6 million, versus $1.3 million in the same quarter of 2025; Q4 net loss was $4.0 million, or $0.22 per share, versus $0.9 million, or $0.05 per share.
Full-year net loss was $9.2 million, or $0.52 per share, compared with $3.0 million, or $0.23 per share, in fiscal 2025.
Adjusted EBITDA loss for the full year was $5.2 million, compared with a gain of $0.2 million a year earlier.
Cash and cash equivalents were $56.0 million at June 30, 2026; the company disclosed a letter of intent for up to $30 million in CHIPS R&D funding, which remains subject to definitive agreement negotiations.
Aeluma, Inc. announced on July 29, 2026 that it signed a letter of intent for up to $30 million of proposed CHIPS and Science Act funding from the U.S. Department of Commerce to support R&D of its non-InP photonics platform. The award remains subject to due diligence, government approvals and definitive award documents, and in connection with final documents Aeluma would issue equity securities to the Department of Commerce with a value equal to the award amount, which may dilute existing shareholders.
Letter of intent for up to $30 million under the CHIPS and Science Act, dated July 29, 2026
Part of the award is to be funded up front, with the remainder paid on a milestone basis
Aeluma would issue equity securities to the U.S. Department of Commerce with an aggregate value equal to the award amount in connection with final documents
Award is not final and depends on due diligence, required approvals and execution of definitive award documents
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aeluma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →